ERDOSTEINE MUCUS REMOVER ON RESPIRATORY

kanker-paru-paru

The lung is an organ that is easily exposed to oxidant substances due to its location, anatomy and function. Everyday the lung epithelium is exposed to self-produced oxidants as a result of normal metabolism, or oxidants which comes from air such as ozone, nitrogen, dioxide, car smoke, cigarette smoke, and so on.

These things will be very harmful to the lung organ because it can trigger some respiratory problems, such as asthma, bronchitis and chronic obstructive pulmonary disease (COPD). One of the three respiratory tract disorders, caused by the inflammatory process due to oxidative stress and accumulated long-acting protease-antiprotease balance.

Almost all patients with COPD run into an acute stage called exacerbation due to accumulation of mucus/ sputum, these stages will contribute to the progression of the disease as well as the loss of lung function, because exacerbations induce inflammation of inflammatory cells such as neutrophils and macrophages. These components will produce proteolysis enzymes such as neutrophil elastase, metalloproteinase, and myeloperoxidase which triggers free radical. According to Prof. Dr. Faisal Yunus, Sp.P(K), Ph.D, FISR on Scientific Meeting of Pulmonology and Respiratory Medicine (PIPKRA) 4th at Jakarta, an imbalance between oxidants and antioxidants will produces oxidative stress (oxidative stress) which has a role in increased inflammation, to avoid it, the role of antioxidants need to be involved in the treatment of COPD because it has a good bioavailability and can change the state of inflammation improvement.

One of the antioxidants that can increase the concentration of intracellular glutathione (natural antioxidants) is the cysteine group, Erdostein which belongs to the mucolytic drug class. Erdostein is one of the choice in the treatment of COPD that works to dilute the sputum and support in sputum response and has the ability to reduce exacerbations.

Erdomex Gabungan

PT. Simex Pharmaceutical Indonesia comes with ERDOMEX in two dosage forms that is capsules Erdosteine 300 mg and syrup 175 mg / 5 ml with vanilla-orange flavour as potent mucolytic in cases of respiratory accompanied by sputum which cause exacerbations such as Bronchitis and COPD with symptoms of cough with phlegm.

Clinical efficacy of Erdosteine for the treatment of chronic bronchitis patients with hypersecretion have been evaluated by double-blind studies by Auber M and Berdah L from the Pulmonology section Bichat Hospital, Paris, France. The result of the study showed that Erdosteine can reduce frequency of cough, severity of cough, difficulty breathing, and dyspnoea.

ERDOMEX Capsules are consumed 2-3 times 1 capsule daily while for syrup can be given to children with weight parameters, Children 15-19 Kg: 2 x 1 Scoop per day; Child 20-30 Kg: 3 x 1 Scoop per day; Child> 30 Kg: 2 x 2 Scoop per day for 7 – 10 days. ERDOMEX does not cause drowsiness so it is suitable consumed both morning, noon, and night.

 

 

 

REFERENSI:

1. M. Cazzola, I. Floriani, C.P. Page. The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: A meta-analysis of individual patient data. Pulmonary Pharmacology & Therapeutics. 2010. pp.135

2.http://www.scribd.com/doc/138717734/Mukolitik-Dan-Antioksidan-Dalam-Terapi-PPOK

3.http://www.klikpdpi.com/jurnal-warta/jri-04-07/dr.Indah%20JRI.htm

4.https://lifestyle.okezone.com/read/2017/05/30/481/1703240/tak-harus-ke-rs-deteksi-dini-ppok-bisa-dilakukan-di-puskesmas

5.Product Profile Erdomex.2018.Jakarta: PT.Simex Pharmaceutical Indonesia

 

Leave a Reply

  • (will not be published)